A Phase 4 interventional study of treprostinil and Crono Five ambulatory pump in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Terminated at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 35th largest by enrollment, is one of 2 that started in 2007, is one of 14 in phase 4, and was the 5th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2007.
This study's enrollment of 8 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 35th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2007, is one of 11 in phase 4, and was the 5th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to be mixed daily and is stable at room temperature, so there is no need for ice packs. In addition, Remodulin is changed every 48hrs, instead of every 12-24 (with ice packs) or every 8 hours (without ice packs) with Flolan. Flolan is given using a type of portable medication pump called the CADD Legacy infusion pump. In this study, Remodulin will be given using a smaller and lighter medication pump called the Crono Five infusion pump. This study will also assess the effect that changing to Remodulin will have on treatment satisfaction and patient quality of life.
Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH, and to improve health related quality of life (HRQOL).
Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the intravenous (IV) and subcutaneous (SC) routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension from the CADD legacy pump to a smaller pump called the Crono Five.
Participation in this study will last approximately 10 weeks. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, exercise tests and patient questionnaires. Participants will have 4 visits during the study and will spend at least 1 night in the hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of one of the following WHO Classifications of pulmonary hypertension:
Group 1 pulmonary arterial hypertension
Associated pulmonary arterial hypertension (APAH):
Exclusion Criteria:
Previous documented evidence of significant parenchymal lung disease as evidenced by pulmonary function tests as follows (any one of the following):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV treprostinil continuous infusion via Crono Five infusion pump.
Drug: treprostinil · Device: Crono Five ambulatory pump
rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
Also known as: Remodulin
Used for administration of IV Remodulin (treprostinil)
Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD)
The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site \[American Thoracic Society (ATS) guidelines; 2002\].
Time frame: Week 8
Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).
Time frame: Week 8
Change From Baseline at Week 8 in World Health Organization (WHO) Functional Classification
WHO functional class is a system to help clinicians determine how limited a patient is in their ability to do the activities of daily living. The scale ranges from class I to class IV. In general, patients with more severe Pulmonary Hypertension (PH) tend to have a higher functional class.
Time frame: Week 8
Change From Baseline at Week 8 in Symptoms of PAH- Fatigue
The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
Time frame: Week 8
Change From Baseline at Week 8 in Symptoms of PAH- Dyspnea
The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
Time frame: Week 8
Change From Baseline at Week 8 in Symptoms of PAH- Edema
The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
Time frame: Week 8
Change From Baseline at Week 8 in PAH Symptoms- Orthopnea
The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
Time frame: Week 8
Change From Baseline at Week 8 in PAH Symptoms- Dizziness
The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
Time frame: Week 8
Change From Baseline at Week 8 in PAH Symptoms- Syncope
The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
Time frame: Week 8
Change From Baseline at Week 8 in PAH Symptoms- Chest Pain
The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
Time frame: Week 8
Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin.
Time frame: Week 8
Change From Baseline at Week 8 in Score on Quality of Life (QOL) Questionnaire - The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and QOL. The CAMPHOR was completed at Baseline and at Week 8. The CAMPHOR consists of 3 scales: 1. A 25-item overall symptoms scale scored 0-25, with a higher score indicating the presence of more symptoms. 2. A 15 item Activity/Functioning scale scored 0-30, where a low score indicates good functioning. 3. A 25-item QoL scale scored 0-25, with a high score indicating poor QoL. Additionally, a total score was recorded by adding up the the scores from the 3 above scales. The Symptom and QoL scales have dichotomous ('True'/'Not true') response options while the Activity/Functioning scale has three-point ('Able to do on own without difficulty'/'Able to do on own with difficulty'/'Unable to do on own') response options. The CAMPHOR score range can be from 0 to 80. A reduction in score denotes improved heath status.
Time frame: Baseline and Week 8
Change From Baseline at Week 8 in Score on Treatment Satisfaction Questionnaire- The Treatment Satisfaction Questionnaire for Medication (TSQM)
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. The TSQM score range can be from 0 to 100. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.
Time frame: Baseline and Week 8
Subject Responses to the Patient Impression of Change Questionnaire (Administered at Week 8 Only)
A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.
Time frame: Week 8
Screening was initiated by investigators at participating study sites 7 to 28 days prior to the Baseline visit. The first subject was enrolled on February 20, 2007 and the last subject completed the study on September 30, 2009. After an extended recruitment period during which no new subjects were enrolled, the study was closed in 2011.
| Milestone | Treprostinil |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site \[American Thoracic Society (ATS) guidelines; 2002\].
| meters | Treprostinil |
|---|---|
| Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD) | -1.2 ± 37.0 |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).
| units on a scale | Treprostinil |
|---|---|
| Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test | 0.08 ± 1.74 |
WHO functional class is a system to help clinicians determine how limited a patient is in their ability to do the activities of daily living. The scale ranges from class I to class IV. In general, patients with more severe Pulmonary Hypertension (PH) tend to have a higher functional class.
| participants | Treprostinil |
|---|---|
| Improved | 3 |
| No change | 3 |
| Worsened | 2 |
The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 1 |
| No change | 4 |
| Worsened | 3 |
The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 1 |
| No change | 6 |
| Worsened | 1 |
The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 0 |
| No change | 6 |
| Worsened | 2 |
The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 0 |
| No change | 8 |
| Worsened | 0 |
The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 1 |
| No change | 5 |
| Worsened | 2 |
The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 0 |
| No change | 8 |
| Worsened | 0 |
The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
| participants | Treprostinil |
|---|---|
| Improved | 0 |
| No change | 7 |
| Worsened | 1 |
A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin.
| minutes | Treprostinil |
|---|---|
| Gather/set-up | 4.4 ± 32.6 |
| Prepare Drug | -50.4 ± 35.3 |
| Connect drug | -13.1 ± 38.1 |
| Change dressing | 3.9 ± 10.8 |
| Total Time | -55.3 ± 77.0 |
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and QOL. The CAMPHOR was completed at Baseline and at Week 8. The CAMPHOR consists of 3 scales: 1. A 25-item overall symptoms scale scored 0-25, with a higher score indicating the presence of more symptoms. 2. A 15 item Activity/Functioning scale scored 0-30, where a low score indicates good functioning. 3. A 25-item QoL scale scored 0-25, with a high score indicating poor QoL. Additionally, a total score was recorded by adding up the the scores from the 3 above scales. The Symptom and QoL scales have dichotomous ('True'/'Not true') response options while the Activity/Functioning scale has three-point ('Able to do on own without difficulty'/'Able to do on own with difficulty'/'Unable to do on own') response options. The CAMPHOR score range can be from 0 to 80. A reduction in score denotes improved heath status.
| units on a scale | Treprostinil |
|---|---|
| CAMPHOR- Symptom Score | -2.1 ± 4.3 |
| CAMPHOR- Activity Score | 1.0 ± 3.9 |
| CAMPHOR- Quality of Life Score | -3.1 ± 3.7 |
| CAMPHOR- Total Score | -4.3 ± 10.7 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. The TSQM score range can be from 0 to 100. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.
| units on a scale | Treprostinil |
|---|---|
| TSQM- Effectiveness Score | -4.9 ± 22.9 |
| TSQM- Side-Effects Score | 7.0 ± 19.0 |
| TSQM- Conveniences Score | 29.2 ± 21.4 |
| TSQM- Global Satisfaction Score | -11.6 ± 31.7 |
A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.
| participants | Treprostinil |
|---|---|
| Symptoms- Much Better | 4 |
| Symptoms- Somewhat Better | 1 |
| Symptoms- About The Same | 1 |
| Symptoms- Somewhat Worse | 1 |
| Symptoms- Much Worse | 1 |
| Time Spent- Much Less | 5 |
| Time Spent- Somewhat Less | 2 |
| Time Spent- About The Same | 0 |
| Time Spent- Somewhat More | 1 |
| Time Spent- Much More | 0 |
| Satisfaction- Much More Satisfied | 4 |
| Satisfaction- More Satisfied | 2 |
| Satisfaction- About The Same | 1 |
| Satisfaction- Less Satisfied | 0 |
| Satisfaction- Much Less Satisfied | 1 |
Collected over Adverse Events (AEs) were assessed upon initiation of Remodulin through to the end of study (Week 8). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treprostinil | — | 3/8 (37.5%) | 8/8 (100%) |
| Event | Treprostinil |
|---|---|
| central line infectionInfections and infestations | 1/8 |
| Fluid overloadCardiac disorders | 1/8 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/8 |
| Right ventricular failureCardiac disorders | 1/8 |
| Event | Treprostinil |
|---|---|
| DiarrhoeaGastrointestinal disorders | 6/8 |
| HeadacheNervous system disorders | 6/8 |
| NauseaGastrointestinal disorders | 6/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/8 |
| FatigueGeneral disorders | 5/8 |
| VomitingGastrointestinal disorders | 4/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/8 |
| FlushingVascular disorders | 3/8 |
| DizzinessNervous system disorders | 2/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/8 |
| Age, Categorical(Participants) | Treprostinil |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 8 |
| >=65 years | 0 |
| Age, Continuous(years) | Treprostinil |
|---|---|
| Mean | 49.5 (45 to 59) |
| Sex: Female, Male(Participants) | Treprostinil |
|---|---|
| Female | 8 |
| Male | 0 |
| Region of Enrollment(participants) | Treprostinil |
|---|---|
| United States | 8 |
| Pulmonary Arterial Hypertension (PAH) etiology(participants) | Treprostinil |
|---|---|
| IPAH | 6 |
| cardiovascular disease (CVD) | 2 |
| Years since PAH diagnosis(years) | Treprostinil |
|---|---|
| Mean | 7 (1.5 to 12.9) |
| World Health Organization (WHO) functional class at time of transition(participants) | Treprostinil |
|---|---|
| Class II | 6 |
| Class III | 2 |
| epoprostenol dose(ng/kg/min) | Treprostinil |
|---|---|
| Mean | 34.05 (7.7 to 71) |
1 further baseline measures are reported on the registry.
The record gives a start of Feb 2007, a primary completion of Sep 2009 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →